蔚蓝生物 (603739.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.4x

Market Cap

CNY 3.05B

MomentumView details →

1D Return

−1.95%

YTD Return

−10.11%

RSI (14)

54.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.4x

Market Cap

CNY 3.05B

RSI (14)

54.2

MomentumView details →

1D Return

−1.95%

YTD Return

−10.11%

ProfitabilityView details →

Gross Margin

44.75%

Net Margin

5.57%

EBITDA Margin

17.55%

ROE (TTM)

4.34%

ROA (TTM)

2.54%

Asset Turnover

0.46x

GrowthView details →

Revenue YoY

+4.23%

EPS YoY

+28.76%

FCF YoY

−19.03%

Revenue CAGR 3Y

+5.51%

EPS CAGR 3Y

+0.00%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.37x

Current Ratio

1.19x

Quick Ratio

0.97x

Div Yield

0.79%

Div Rate

CNY 0.10

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

1.40B

Net Income (TTM)

78.10M

Op. CF (TTM)

124.59M

Latest newsMore news →

Weilan Biological released its 2026 first-half results, reporting revenue of 710 million yuan, up 8.80% year-on-year, and net profit attributable to shareholders of 38.56 million yuan, up 44.33%.9d ago

Similar companies

Disc Medicine, Inc.IRON Immunome, Inc.IMNM NewAmsterdam Pharma Company N.V.NAMS Beam Therapeutics Inc.BEAM 凯因科技688687.SH uniQure N.V.QURE Find similar companies →

Latest newsMore news →

Weilan Biological released its 2026 first-half results, reporting revenue of 710 million yuan, up 8.80% year-on-year, and net profit attributable to shareholders of 38.56 million yuan, up 44.33%.9d ago